Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1320-1326

  Iversen, Ane B ^a   Busk, Morten ^a   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; MITOFLAXONE; OXYGEN; VADIMEZAN; VASCULAR TARGETING AGENT; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; CANCER CONTROL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HYPOXIA; IRRADIATION; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TREATMENT RESPONSE; TUMOR MODEL; ASSAY; CLINICAL EVALUATION; CLINICAL STUDY; FOOT; MACHINE; OXYGEN ELECTRODE; OXYGENATION; PROTEIN BINDING; RADIATION RESPONSE;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CHEMORADIOTHERAPY; DIPHOSPHATES; FEMALE; FLAVONOIDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; OXYGEN; STILBENES; X-RAY THERAPY; XANTHONES;

EID: 84884547645     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.825050     Document Type: Article

References (43)

1. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. P rolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807-12
2. Folkman J. How is blood vessel growth regulateDin normal and neoplastic tissue? Cancer Res 1986;46:467-73
3. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: A dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770-5
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10
5. Stoeltzing O, Ellis LM. The role of microvasculature in metastasis formation. In: Siemann DW, editor. Vasculartargeted therapies in oncology. Chichester: John Wiley & Sons, Ltd.; 2006. p. 31-62
6. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, et al. Differentiation and defi nition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-20
7. Horsman MR, Siemann DW. PathophysiologicaLeffects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39
8. National Cancer Institute Website: Www.cancer.gov/clinicaltrials
9. Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, et al. ClinicaLoutcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011;50:630-5
10. Cao C, Wang J, BunjhoOh, Xu Y, Fang H. RIsk profi le of bevacizumab in patients with non-small cell lung cancer: A meta-analysis of randomized controlled trials. Acta Oncol 2012;51:151-6
11. Patterson DM, RustiNgJS. V ascular damaging agents. C lin Oncol 2007;19:443-56
12. Siemann DW, Warrington KH, Horsman MR. T argeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother Oncol 2000;57:5-12
13. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674-87
14. Baguley B C. A ntivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8
15. Tozer GM, Kanthou C, Baguley B C. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35
16. Lara P N Jr, Douillard J Y, Nakagawa K, von Pawel J, McKeage MJ, Albert I, et al. Randomized phase III placebocontrolled triaLof carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Onol 2011;29:2965-71
17. Frü h M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, et al. Carboplatin and paclitaxel plus ASA404 as fi rst-line chemotherapy for extensive-stage small-cell lung cancer: A multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2013;14:34-9
18. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18:189-97
19. Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients witHadvanced solid tumors. Clin Cancer Res 2012;18:1415-25
20. Overgaard J. S imultaneous and sequential hyperthermia and radiation treatment of an experimental tumor anDits surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980;6:1507-17
21. Nielsen T, Murata R, Maxwell RJ, S t ød kilde-J ør gensen H, stergaard L, Horsman MR. Preclinical studies to predict the effi cacy of the vascular changes induced by combretastatin A-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys 2008;70:859-66
22. Horsman MR, Nordsmark M, Khalil A A, Hill SA, Chaplin DJ, Siemann DW, et al. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol 1994;33:371-6
23. M urata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother Oncol 2001;60:155-61
24. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001;156:503-9
25. Horsman M R, Murata R. Combination of vascular targeting agents with thermal and radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518-23
26. Murata R, Horsman MR. Tumour specifi c enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2004;20:393-404
27. Horsman MR, Murata R. V ascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047-55
28. Bertelsen LB, Shen YY, Nielsen T, S t ød kilde-J ør gensen H, Lloyd GK, Siemann DW, et al. Vascular effects of plinabulin (NPI-2358) and the infl uence on tumour response wheNgiven alone or combined with radiation. Int J Radiat Biol 2011;87:1126-34
29. Wachsberger PR, Burd R, MarerOn, Daskalakis C, Ryan A, McCue P, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005;11:835-42
30. Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, DahLo. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol 2001;61:313-20
31. El-Emir E, Boxer G M, Petrie I A, Boden R W, Dearling J L, Begent RH, et al. Tumour parameters affected by combretastatin A-4 p hosphate therapy in a human colorectal xenograft modeLin nude mice. Eur J Cancer 2005;41:799-806
32. Zhao D, Jiang L, Hahn E W, Mason R P. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005;62:872-80
33. Horsman M R, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between fl avone acetic acid and hyperthermia. Int J Hyperthermia 1996;12:779-89
34. Murata R, Overgaard J, Horsman MR. C omparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204
35. Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998;42:895-8
36. Horsman MR, Wouters BG, Joiner MC, Overgaard J. The oxygen effect and fractionated radiotherapy. In: Van Der Kogel AJ, Joiner M, editors. Basic clinical radiobiology, 4th ed. Hodder Arnold: London; 2009. p 207-16
37. Salmon H W, Siemann D W. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006;12:4090-4
38. Folkes LK, Christlieb M, Madej E, Stratford MRL, Wardman P. Oxidative metabolism of combretastatin A-1 produces quinine intermediates with the potential to bind tOnucleophiles and to enhance oxidative stress viAfree radicals. Chem Res Toxicol 2007;20:1885-94
39. RofstaDeK, Galappathi K, Mathiesen B, RuuDeBM. F luctuating and diffusion limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 2007;13:1971-8
40. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin ExPMetastasis 2009;26:19-34
41. Ellingsen C, Hompland T, Mathiesen B, RofstaDe K. M icroenvironment-associated lymph node metastasis of human cervical carcinoma xenografts. Acta Oncol 2012;51:465-72
42. P àe z-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vi ñ als F, et al. Antiangiogenic therapYelicits malignant progression of tumors to increased locaLinvasion and distant metastasis. Cancer Cell 2009;15:220-31
43. Ebos JML, Lee CR, Cruz-Munoz W, BjamasoNgA, Christensen JG, Kerbel RS. Accelerated metastasis after shortterm treatment witHa potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9